{"id":6913,"date":"2002-11-13T14:20:18","date_gmt":"2002-11-13T13:20:18","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=6913"},"modified":"2014-06-03T17:39:59","modified_gmt":"2014-06-03T17:39:59","slug":"study-suggests-kaletracombivir-is-better-tolerated-pep-than-combivirnelfinavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/6913","title":{"rendered":"Study suggests Kaletra\/Combivir is better tolerated PEP than Combivir\/nelfinavir"},"content":{"rendered":"<p><strong>Graham McKerrow, HIV i-Base<\/strong><\/p>\n<p><strong>Lopinavir\/ritonavir (LPV, Kaletra) and AZT\/3TC (zidovudine and lamivudine, Combivir) is \u201csignificantly\u201d better tolerated as a post-exposure prophylaxis (PEP) than AZT\/3TC plus nelfinavir, according to French researchers.<\/strong><\/p>\n<p>Dr Christian Rabaud, of the Service des Maladies Infectieuses et Tropicales, Vandoeuvre-les-Nancy, France, presented the preliminary findings of a study at the 42nd ICAAC. Rabaud says the improved tolerance could be because the intrinsic gut tolerance of LPV is better than that of nelfinavir.<\/p>\n<p>The researchers conducted a prospective study of patients seeking HIV prophylaxis at six hospitals in eastern France. Ninety-eight patients were prescribed LPV and AZT\/3TC over a 12-month period. The patients were 21 healthcare workers, 56 people who were exposed through sexual contact, two intravenous drug users, and 19 who were exposed to HIV by other means.<\/p>\n<p>The HIV serological status of the source person could be determined in 30 (28.5%) cases; the source person was recognised as seropositive in 16 (53.5%) of these cases. Three people had not begun the prescribed PEP. Nine people were lost to follow-up. Tolerability could be evaluated in 86 people.<\/p>\n<p>In 17 cases, PEP was discontinued before Day Five because the source person was recognised as HIV-seronegative or because the injury was reassessed as \u201clow-risk\u201d. In three (18%) of these cases, side effects were noted before this discontinuation. In 17 other cases, PEP was discontinued for adverse effects (median treatment period = seven days). Fifty-two people completed the 28 days of AZT\/3TC plus LPV PEP and 27 (52%) experienced at least one adverse effect: diarrhoea (78%), nausea (63%), asthenia (48%) and\/or skin rash (15%). Finally, in the 69 people who should have completed PEP, 44 (64%) experienced at least one side effect.<\/p>\n<p>The researchers conclude: \u201cTolerability of [AZT\/3TC plus LPV] PEP appeared significantly better when compared with [AZT\/3TC plus nelfinavir] PEP (side effects : 64% vs 85%; p &lt; 0,003).<\/p>\n<h3>Comment<\/h3>\n<p><strong>Although encouraging it has to be emphasised that this was a single arm study compared to an historical control.<\/strong><\/p>\n<p><strong>This limits the conclusions which can be drawn from the study markedly.<\/strong><\/p>\n<p>Reference:<\/p>\n<p>C Rabaud, C Burty, F Truchetet et al. Tolerability of Post-Exposure Zidovudine\/Lamivudine + Lopinavir\/Ritonavir Prophylaxis of HIV Infection. Presentation Number: H-177. Poster Board Number: 177<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Graham McKerrow, HIV i-Base Lopinavir\/ritonavir (LPV, Kaletra) and AZT\/3TC (zidovudine and lamivudine, Combivir) is \u201csignificantly\u201d better tolerated as a post-exposure prophylaxis (PEP) than AZT\/3TC plus nelfinavir, according to French researchers. Dr Christian Rabaud, of the Service des Maladies Infectieuses et &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[97],"class_list":["post-6913","post","type-post","status-publish","format-standard","hentry","category-conference-reports","tag-icaac-42nd-2002"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/6913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=6913"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/6913\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=6913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=6913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=6913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}